Exploration of thiazolidine‐2,4‐diones as tyrosine kinase inhibitors: Design, synthesis, ADMET, docking, and antiproliferative evaluations
Nada A. A. M. Aziz, Riham F. George, Khaled El‐Adl, Walaa R. Mahmoud
Abstract
Abstract As dual EGFR and VEGFR‐2 inhibitors, 22 innovative thiazolidine‐2,4‐diones were modeled, constructed, and measured for their anticancer performance versus four human neoplasms HCT‐116, MCF‐7, A549, and HepG2. Molecular docking and MD simulation were performed to inspect the binding technique of the proffered congeners with the EGFR and VEGFR‐2 receptors. Evidence realized thanks to the docking inquests was vastly consistent together with that detected through the biological screening. Structures 14a and 14g emerged as the most active compounds toward HCT116 (IC 50 = 6.01 and 7.44 µM), MCF‐7 (IC 50 = 5.77 and 7.23 µM), A549 (IC 50 = 5.35 and 5.47 µM) and HepG2 (IC 50 = 3.55 and 3.85 µM) tumefaction cells. Compounds 14a and 14g exhibited higher events than sorafenib (IC 50 = 5.05, 5.58, 4.04, and 4.00 µM) against HepG2 instead subordinate incidents concerning A549, MCF‐7, and HCT116, parallelly. Nevertheless, these compounds signified weightier performance than erlotinib (IC 50 = 13.91, 8.20, 5.49, 7.73, and µM), with respect to the four cell lines. Compounds having the best activity against the four cell lines, 12a–f , 13a–d , and 14a–g were chosen to appraise their in vitro VEGFR‐2 and EGFR T790M inhibiting activities. The best results were for compounds 14a and 14g compared to sorafenib and erlotinib, respectively, with IC 50 values of 0.74 and 0.78 µM and 0.12 and 0.14 µM, respectively. Moreover, 13d , 14a , and 14g showed an adequate in silico calculated ADMET profile. The current investigation presents novel candidates for future optimization to construct mightier and eclectic binary VEGFR‐2/EGFR T790M restrainers with higher antitumor effects.